ZYXI

ZYXI

USD

Zynex Inc. Common Stock

$2.110+0.060 (2.927%)

Reaalajas hind

Healthcare
Medical Distribution
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$2.050

Kõrge

$2.110

Madal

$2.000

Maht

0.07M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

63.8M

Tööstusharu

Medical Distribution

Riik

United States

Kauplemisstatistika

Keskmine maht

0.27M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $1.66Praegune $2.110Kõrge $10.62

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 10. juuni 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

ZYXI: Zynex Inc. Common Stock – Navigating Legal Clouds and Price Swings

Stock Symbol: ZYXI Generate Date: 2025-06-10 21:28:19

Let's break down what's been happening with Zynex Inc. (ZYXI) and what the data might be telling us.

Recent News Buzz: A Storm of Lawsuits

The news around Zynex lately has been overwhelmingly negative. We're seeing a flurry of announcements from various law firms – Rosen Law Firm, The Gross Law Firm, Schall Law Firm, Faruqi & Faruqi, and Levi & Korsinsky, among others. They're all talking about the same thing: a securities fraud class action lawsuit against Zynex.

Essentially, these firms are encouraging investors who lost money, particularly those who bought shares between March 13, 2023, and a specific period, to join these lawsuits. The consistent drumbeat of "securities fraud," "investor losses," and "class action deadlines" paints a pretty grim picture. It suggests there might be some serious questions about how the company communicated with its investors during that time. This kind of news usually makes investors nervous, and for good reason.

Adding to this, we also saw some analyst downgrades in late April. RBC Capital lowered its price target from $5 to $4, and HC Wainwright & Co. slashed theirs from $15 to $8, even while maintaining a "Buy" rating. This happened right after Zynex reported its first-quarter 2025 financial results on April 29th. So, it seems the financial performance wasn't exactly stellar, leading analysts to temper their expectations.

Price Check: A Rocky Ride Down, Then Some Stability

Looking at the stock's journey over the last few months, it's been quite a ride. Back in early March, ZYXI was trading around $7.17. Then, boom, a massive drop on March 12th, plunging to the $3-$5 range, and it kept sliding. By late April, it hit a 52-week low of $1.66.

Since that low point on April 30th, the stock has shown some signs of stabilizing, mostly trading in the $2.00 to $2.50 range. As of today, June 10th, the price is around $2.19. So, while it's well off its March highs, it has managed to bounce a bit from its recent bottom. Volume has been pretty varied, with some spikes during the initial drops and then more moderate levels.

Outlook & Ideas: Proceed with Caution

Putting it all together, the picture for ZYXI is quite mixed, leaning towards caution.

The overwhelming negative news about the class-action lawsuits is a significant overhang. This kind of legal trouble can be costly and distracting for a company, and it often erodes investor confidence. It's a big red flag.

On the other hand, the stock has found some footing after its sharp decline. The AI prediction for the next couple of days is pretty flat, showing a 0.00% change today, then a slight dip of -0.01% tomorrow, followed by a small positive bump of 0.52% the day after. This suggests the AI doesn't see any immediate dramatic moves, either up or down, in the very short term.

AIPredictStock.com's recommendation data, however, offers a slightly different perspective, highlighting "Bullish Momentum" and "Undervalued Gem" tags, with a "Robust technical indicators reveal a strong bullish breakout." It points to technical reasons like a positive DMI, MACD golden cross, and a surge in OBV (On-Balance Volume) indicating buying interest. It also notes a low P/E ratio (4.6x vs. industry 6.8x) as a fundamental positive.

However, it's crucial to note the significant fundamental negatives also highlighted: revenue growth at -42.9%, a low Return on Equity (-27.5%), and a very high Debt-to-Equity ratio (351.59%). These are serious concerns that contradict the "undervalued gem" idea, especially the debt. The AI also projects an upward trend with a potential target of $1.00, which is actually below the current price, creating a bit of a mixed signal from the AI's own predictions.

Given the heavy legal cloud and the mixed signals from the AI's detailed reasons (strong technicals vs. weak fundamentals), a "hold" or "wait and see" approach seems most prudent for now. The stock has stabilized, but the legal issues could easily trigger more volatility.

  • Potential Entry Consideration: If you're a very risk-tolerant investor looking for a rebound play, and you believe the legal issues are already priced in or will resolve favorably, a potential entry might be considered around the current price of $2.19, or perhaps on a slight dip towards the $2.15-$2.18 range, which the recommendation data flags as potential entry points. This is a highly speculative move, betting on the technical rebound outweighing the fundamental and legal risks.
  • Potential Exit/Stop-Loss Consideration: For those already holding, or if you decide to enter, setting a clear stop-loss is vital. The recommendation data suggests a stop-loss at $1.98. This makes sense as it's below recent lows and would signal a breakdown of the current stabilization. For taking profits, the recommendation suggests $2.24, which is a very tight target, indicating short-term trading. Given the broader negative sentiment, quick profit-taking might be a sensible strategy if the stock does tick up.

Company Context: Medical Devices Under Scrutiny

Zynex Inc. operates in the medical distribution sector, specializing in non-invasive medical devices for pain management and rehabilitation. They also have products for fluid monitoring. The company has about 1000 employees. The core business itself, providing medical devices, is generally stable, but the current legal challenges are a direct threat to that stability and investor confidence. The fact that their revenue growth is negative and debt is high, as noted in the recommendation data, means the company is facing operational headwinds alongside the legal ones.

Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks carries inherent risks, and past performance is not indicative of future results. Always conduct your own thorough research and consult with a qualified financial professional before making any investment decisions.

Seotud uudised

PR Newswire

ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and...

Vaata rohkem
ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit
PR Newswire

Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXI

The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the...

Vaata rohkem
Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXI
PR Newswire

ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zynex, Inc. ("Zynex" or "the...

Vaata rohkem
ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm
GlobeNewswire

ZYXI Investors Have the Opportunity to Lead the Zynex Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in

Vaata rohkem
ZYXI Investors Have the Opportunity to Lead the Zynex Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
PR Newswire

Faruqi & Faruqi Reminds Zynex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 - ZYXI

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company")...

Vaata rohkem
Faruqi & Faruqi Reminds Zynex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 - ZYXI
PR Newswire

ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zynex, Inc. ("Zynex" or "the...

PR Newswire

May 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZYXI

Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit. CLASS...

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 12. juuni 2025, 15:14

LangevNeutraalneTõusev

58.7% Kindlus

Risk ja kauplemine

Riskitase4/5
Kõrge risk
Sobib
Väärtus
Kauplemisjuhend

Sisenemispunkt

$2.05

Võta kasum

$2.18

Peata kahjum

$1.83

Põhitegurid

DMI näitab langustrendi (ADX:31.2, +DI:13.0, -DI:27.4), mis viitab ettevaatlikkusele
Praegune hind on tugitasemele ($2.06) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 1.9x keskmisest (3,534), mis viitab suurenenud turuosalusele
MACD -0.0197 on signaalijoone -0.0186 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.